Its revenue increased by 16.4% to ₹493.66 crore from ₹424.2 crore in the previous year. Meanwhile, its profit declined 16.9% to ₹70.81 crore from ₹85.2 crore.
Its earnings before interest, tax, depreciation and amortisation declined 2.8% to ₹111.2 crore from ₹114.4 crore in the previous year. Meanwhile, its margins contracted to 23% from 27% in the year-ago period.The company’s cash on books was ₹839.8 crore.
Revenue for the domestic business increased 16.2% to ₹146.6 crore from the previous year, and it was up 4% sequentially.
Meanwhile, the international business was up 16.1% from the previous year and 14.1% from the previous quarter to ₹342.8 crore.Within the international segment,
revenue from the European Union increased 25.7% to ₹129.1 crore, and it was up 23.1% sequentially.
For rest of the world (RoW) it increased 9.5% annually and 7.3% sequentially to 165 crore.
Infusion therapy witnessed a 5% increase from the previous year and a marginal increase from the previous quarter to ₹274.3 crore, while Renal therapy too saw a 15.1% increase annually and 1.3% sequentially to ₹44.8 crore.
Shares of Poly Medicure are trading 7.1% lower at ₹1,395.6. The stock has declined 21.5% in the past month and 42.4% in the past year.
Also Read: Hexaware Tech shares fall for second straight day as JPMorgan, HSBC downgrade, cut price target
